2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
14
Fallopian Tube Neoplasms
13
Neoplasms
9
Breast Neoplasms
8
Prostatic Neoplasms
7
Carcinoma, Ovarian Epithelial
7
Endometrial Neoplasms
5
Pancreatic Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Metastatic Castration Resistant Prostate Cancer
2
Lung Neoplasms
2
Leiomyosarcoma
2
Carcinoma, Transitional Cell
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Myeloproliferative Disorders
1
Interventions
Doxorubicin
142
Ifosfamide
85
Radiotherapy
82
Cyclophosphamide
72
Gemcitabine
63
Filgrastim
54
pembrolizumab
43
pazopanib
40
Etoposide
39
Docetaxel
39
Vincristine
37
Trabectedin
37
Cisplatin
35
Nivolumab
32
Magnetic Resonance Spectroscopy
26
Irinotecan
26
Carboplatin
25
Temozolomide
23
Surgical Procedures, Operative
23
Radiation
22
Ipilimumab
22
Bevacizumab
20
Blood Specimen Collection
19
Granulocyte Colony-Stimulating Factor
18
Biopsy
18
eribulin
17
Sirolimus
17
Mesna
17
Melphalan
17
Dactinomycin
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
rucaparib
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts